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Background: Carbonic anhydrase (CA) IX is a surface-expressed protein that is upregulated by the hypoxia
inducible factor (HIF) and represents a prototypic tumor-associated antigen that is overexpressed on renal cell
carcinoma (RCC). Therapeutic approaches targeting CAIX have focused on the development of CAIX inhibitors and
specific immunotherapies including monoclonal antibodies (mAbs). However, current in vivo mouse models used to
characterize the anti-tumor properties of fully human anti-CAIX mAbs have significant limitations since the role of
human effector cells in tumor cell killing in vivo is not directly evaluated.
Methods: The role of human anti-CAIX mAbs on CAIX+ RCC tumor cell killing by immunocytes or complement was
tested in vitro by antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity
(CDC) and antibody-dependent cellular phagocytosis (ADCP) as well as on CAIX+ RCC cellular motility, wound
healing, migration and proliferation. The in vivo therapeutic activity mediated by anti-CAIX mAbs was determined
by using a novel orthotopic RCC xenograft humanized animal model and analyzed by histology and FACS staining.
Results: Our studies demonstrate the capacity of human anti-CAIX mAbs that inhibit CA enzymatic activity to result
in immune-mediated killing of RCC, including nature killer (NK) cell-mediated ADCC, CDC, and macrophage-
mediated ADCP. The killing activity correlated positively with the level of CAIX expression on RCC tumor cell lines.
In addition, Fc engineering of anti-CAIX mAbs was shown to enhance the ADCC activity against RCC. We also
demonstrate that these anti-CAIX mAbs inhibit migration of RCC cells in vitro. Finally, through the implementation
of a novel orthotopic RCC model utilizing allogeneic human peripheral blood mononuclear cells in NOD/SCID/
IL2Rγ−/− mice, we show that anti-CAIX mAbs are capable of mediating human immune response in vivo including
tumor infiltration of NK cells and activation of T cells, resulting in inhibition of CAIX+ tumor growth.
Conclusions: Our findings demonstrate that these novel human anti-CAIX mAbs have therapeutic potential in the
unmet medical need of targeted killing of HIF-driven CAIX+RCC. The orthotopic tumor xenografted humanized
mouse provides an improved model to evaluate the in vivo anti-tumor capabilities of fully human mAbs for RCC
therapy.
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Globally, an estimated 270,000 new cases and 116,000
deaths attributed to kidney cancer occur each year [1].
Greater than 90 % of kidney neoplasms are classified as
renal cell carcinoma (RCC), of which upwards of 30 %
progress towards metastatic disease [2, 3]. Treatment
of RCC can be broadly grouped into either immuno-
therapy or targeted therapy. Immunotherapy with high
dose interleukin-2 (IL-2) alone or in combination with
interferon-α (IFN-α) has historically been a frontline of
defense against RCC [4]. More recently, checkpoint con-
trol inhibitors and targeted therapies have shown great
promise in combating RCC [2, 5, 6]. The currently ap-
proved targeted therapies against RCC include a monoclo-
nal antibody (mAb) that blocks vascular endothelial growth
factor from binding its receptor (bevacizumab), tyrosine
kinase inhibitors (TKIs; sunitinib, sorafenib, pazopanib, and
axitinib), and mammalian target of rapamycin inhibitors
(everolimus and temsirolimus). These therapies alone or in
combination have shown promise towards combating RCC
[7, 8], but a complete and curative regimen by these drug
or immunotherapy agents remains elusive.
Tumor-associated antigens are the focus of both diag-
nostic and therapeutic strategies against many forms of
cancer, and carbonic anhydrase (CA) IX is the most
well characterized antigen associated with RCC [9, 10].
CAIX is a trans-membrane protein that alters the pH
of the extracellular microenvironment towards acidity
during hypoxia [10–12]. Expression of CAIX is con-
trolled by the tumor suppressor von Hippel-Lindau fac-
tor, and nearly all forms of clear cell RCC express CAIX,
which is absent on normal kidney tissue [9]. Expression of
CAIX on RCC is a prognostic factor, in that reduced
CAIX expression is closely associated with the progression
of disease [13] while expression of CAIX correlates with
the efficacy of some treatments [4]. Thus, although ex-
pression of CAIX may provide RCC tumors with a growth
advantage [14–16], it also conveys a level of susceptibility
to treatment.
Multiple immunotherapeutic approaches center on
targeting CAIX, including cellular-based strategies to
vaccinate against CAIX [17–19] and mAbs that bind
CAIX [20–23]. The chimeric antibody girentuximab
(Rencarex®, Wilex) has been extensively tested in clinical
trials [24], including its use alone, coupled to radioiso-
topes, in combination with cytokines, and in conjunction
with chimeric antigen receptor (CAR) T cell therapy
[25]. Results were recently released from a Phase 3 trial
testing the efficacy of girentuximab alone versus placebo
to limit disease progression in patients having under-
gone nephrectomy of non-metastatic clear cell RCC
[26]. While the study objectives were not met, prelimin-
ary data indicate that a higher degree of efficacy was
seen in younger patients whose tumors expressed highlevels of CAIX. These findings, in conjunction with other
clinical and preclinical data, emphasize the potential for
anti-CAIX mAbs in treating RCC, but also highlight the
need for new anti-CAIX mAbs that may have more potent
anti-tumor properties [2, 27].
In seeking to develop novel therapeutic agents against
RCC and other CAIX-expressing malignancies, we
sought to further characterize a panel of high affinity,
fully human antibodies against CAIX that we had previ-
ously described [23]. We focused on two high-affinity
antibodies that inhibit CA activity, but have disparate
capabilities to induce CAIX internalization. We exam-
ined their ability to elicit cellular immune responses to
CAIX expressing tumor cells both in vitro and in vivo.
Our results demonstrate that these two human anti-
CAIX mAbs mediate immune killing of CAIX+ tumor
cells in vitro and show potent therapeutic activity
in vivo.
Results
Fully human anti-CAIX antibodies mediate ADCC in vitro
Our previous report defined a novel panel of fully hu-
man anti-CAIX antibodies that varied in their affinity,
capacity to inhibit the enzymatic activity of CAIX, and
ability to induce internalization of CAIX upon binding
[23]. To ascertain the ability of these antibodies to medi-
ate immune cell killing of CAIX-expressing RCC cells,
we chose to analyze high affinity scFv-Fc antibodies that
either inhibited the CA activity of CAIX, but did not
internalize (G37 and G39), or showed minimal to mod-
est inhibition of CA activity and induced internalization
of CAIX (G10, G36, and G119) [23]. We utilized RCC
cell lines with high CAIX (SKRC-09, Fig. 1a), moderate
CAIX (SKRC-52, Fig. 1b), or no CAIX expression
(SKRC-59, Fig. 1c), and found that all five antibodies
mediate ADCC in accordance with the relative expres-
sion level of CAIX on RCC lines (Fig. 1 and Additional
file 1: Figure S1A) [28]. Interestingly, the antibodies that
induce internalization of CAIX (G10, G36, and G119)
showed comparable ADCC activity to those that do not
internalize (G37 and G39), suggesting that, upon binding
to the CAIX epitope (s), the Fc regions of all antibodies
from both groups are properly positioned to promote
Fcγ receptor (FcγR)-mediated killing.
Both internalizing and non-internalizing anti-CAIX
antibodies limit RCC migration
In light of observations that CAIX activity has been
linked to the capacity of tumor cells to migrate and
grow, we questioned whether antibodies that are capable
of blocking CAIX activity could limit RCC migration
in vitro [29]. Two full-length IgG1 anti-CAIX mAbs that
exhibited a high (G37) or moderate (G119) capacity to
block CA activity and were internalizing or not, respectively,
Fig. 1 ADCC activity of anti-CAIX scFv-Fc antibodies. Anti-CAIX scFv-Fc
antibodies G10, G36, G37, G39, and G119, were tested for ADCC activity
against RCC cells with high CAIX expression (SKRC-09, a), moderate
CAIX expression (SKRC-52, b), and low/negative CAIX expression (SKRC-
59, c). Human PBMC were isolated from healthy donors, and total
PBMC counted as effector cells (E) in co-culture with the respective
target RCC cell line (T). The concentration of antibodies was 5 μg/ml.
Culture supernatant after four hours of co-culture was examined for
LDH as a measure of cytotoxicity. Data represent the mean of three
independent experimental values, ± S.E.M each experiment performed
in triplicate.. * represents p value of two-way ANOVA< 0.05, compared
to control antibody
Fig. 2 Anti-CAIX IgG1mAbsmodulate themotility of CAIX+ RCC. (a) Cell
migration assayed by transwell migration, using CAIX+ SKRC-52 cells and
treatment with anti-CAIXmAbs (2.5 μg/ml), non-specific control antibody
(2.5 μg/ml), or acetazolamide (AZ, 100 μM). Migrationwasmeasured after
24 h, in response to HGF in the lower chamber. (b) Wound healing assay of
CAIX+ RCC cells in the presence of anti-CAIXmAbs (10 μg/ml), non-specific
control antibody (10 μg/ml), or acetazolamide (AZ, 100 μM). Confluent
monolayer of SKRC-52 cells werewounded, and after 24 h healing
calculated as the area not containing cells asmeasured bymicroscopy. (c)
Cellular proliferation of CAIX+ RCC cells, measured in conditions as above,
through 4 days post-treatment. All data representmean values ± S.D. of
three independent experiments, each experiment performed in triplicate.
* represents p value of student t-test < 0.05, compared to control antibody
Chang et al. Molecular Cancer  (2015) 14:119 Page 3 of 13were tested. In a transwell assay (Fig. 2a), both anti-CAIX
mAbs G37 and G119 showed inhibition of RCC cell migra-
tion comparable to that seen with the CA inhibitor acetazol-
amide. Similarly, both mAbs showed a capacity to inhibit
RCC growth in wound healing assays (Fig. 2b) that mirrored
inhibition seen with acetazolamide treatment [29]. An iso-
type control IgG1 did not have these properties. Further-
more, cell proliferation remained unaltered in the presence
of anti-CAIX mAbs in a MTT assay (Fig. 2c), suggesting
that anti-CAIX mAbs do not directly affect RCC viability.
Fig. 3 The antibody-mediated killing activities of wild type and Fc
mutant G37 and G119 on CAIX expressing tumor cells. (a) Anti-CAIX
mAbs (G37 and G119) and the variants (mG37 and mG119) were
tested for ADCC activity with human PBMCs in a dose dependent
manner. CAIX+ SKRC-52 cells were incubated with human PBMCs at
a ratio of 1:25 and the indicated concentrations of antibodies, and
cytotoxicity measured by LDH release in the culture supernatant.
Data represent three independent experiments, each performed in
triplicate. (b) CDC activity was determined by culture of rabbit serum
with SKRC-52 cells, and cytotoxicity measured as above after 6 h. Data
represent three independent experiments, each performed in triplicate.
(c) ADCP activity was determined in vitro by flow cytometry, measuring
the uptake of fluorescently labeled SKRC-52 cells (PKH) by monocyte
derived human macrophages. Data represent the mean percentage of
PKH+CD16+ macrophages from two experiments, as determined by
FACS, each experiment performed in triplicate. All data points represent
the mean value ± S.E.M.. *, **, and *** represent p value of two-way
ANOVA < 0.05, 0.01, and 0.005, respectively (grey asterisks, compared to
wild type IgG1; black asterisks, compared to control IgG1)
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G119 IgG1 mAbs are capable of inhibiting RCC migration.
Anti-CAIX mAbs can be engineered to enhance ADCC
effector function
Several studies have demonstrated that mutations in the
Fc region of IgG1 can enhance antibody affinity for FcγR
in a manner that increases their effector activity [30, 31].
We engineered these mutations into the Fc region of
G37 and G119 IgG1 by changing amino acids S239D/
H268F/S324T/I332E (which do not only alter FcγR bind-
ing of IgG1 but also C1q binding) [31, 32], and then ex-
amined the capacity of these mutations to enhance
effector function through ADCC, CDC and ADCP. In
comparison to native IgG1 formats, the mutated forms
of both G37 and G119 (mIgG1) demonstrated increased
effector activity in ADCC assays (Fig. 3a). Both wild type
G37 and G119 and their mIgG1 isoforms showed CDC
and ADCP activity in a dose dependent fashion (Figs. 3b
and c, and Additional file 1: Figure S1b). However, the
mIgG1 isoforms while showing an increasing trend in
killing, did not show statistically significant enhance-
ment of CDC activity compared to wild type IgG1. In
addition, the mIgG1 isoforms showed a small but not
significantly lower ADCP activity compared to wild type
IgG1. These experiments demonstrate that mutations in
the Fc region of IgG1 can enhance the ADCC effector
activity of the anti-CAIX mAbs in vitro.
Anti-CAIX mAbs limit tumor growth in an orthotopic
model of RCC
The capacity of the anti-CAIX mAbs to elicit immune
killing of RCC, and in turn their therapeutic potential, is
best tested in vivo. While several reports have utilized
xenograft models of RCC to assay the mechanisms and
efficacy of targeted therapies [33], these models are lim-
ited in their capacity to assay the efficacy of antibody
therapies that leverage human immune cell killing of
engrafted tumors. To address this shortcoming, we de-
veloped a novel humanized mouse model that utilized
allogeneic human peripheral blood mononucleated cells
(PBMC) to mediate inhibition of orthotopic RCC tumor
growth (Fig. 4). Orthotopic models offer a means to
mimic clinically relevant tumor growth [5, 34] (Fig. 4a),
which we hypothesized could be inhibited by treatment
with human immune cells and subsequent administra-
tion of anti-CAIX mAbs (Fig. 4b). Utilizing this model,
we tested wild type IgG1 and mIgG1 formats of anti-
CAIX G37 and G119 and compared the ability of these
mAbs to inhibit tumor growth versus PBS or a non-
specific IgG1 control.
To demonstrate the specific killing activity of fully hu-
man anti-CAIX mAbs against CAIX-expressing cells, we
engineered the rapidly growing CAIX-negative RCC cellline SKRC-59 to stably express human CAIX (CAIX+
SKRC-59) by lentiviral transduction. Furthermore, in
light of the known varied ability of healthy human
PBMC to elicit ADCC responses, we first pre-selected
PBMC from a single donor that exhibited the highest
Fig. 4 Design of the orthotopic RCC model and humanization with PBMC. (a) Diagram of the orthotopic implantation and engraftment of a
human RCC line, transduced with luciferase, into the subrenal capsule of NSG mice. Subsequent to tumor engraftment, human PBMC and then
anti-CAIX or control IgG1 treatment was administered to mice intravenously, with repeated dosing of treatment and measurement of tumor
growth by BLI every 3–4 days. (b) Outline of establishment and treatment of the orthotopic model
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of anti-CAIX G37 in vitro (Additional file 2: Figure S2).
Following engraftment of tumors, and injection of mice
on day 4 with the human PBMC that exhibited high
ADCC, and with mAbs on day 10, all groups showed a
small but appreciable decrease in tumor growth beyond
one week post engraftment (Fig. 5a). Through two weeks
post tumor engraftment, no significant difference in
tumor growth was seen between treatment groups by
BLI analysis. However, at three weeks, mice treated with
PBS or an irrelevant IgG1 showed an increased growth
of the orthotopic tumors. In contrast, mice treated with
anti-CAIX mAbs demonstrated significantly less tumor
growth by BLI analysis (Fig. 5b). At day 14 post tumor
engraftment (10 days after PBMC injection and 4 days
after antibody injection), gross pathological examination
revealed a more pronounced growth of the tumors in
mice treated with control antibody and PBS than mice
treated with anti-CAIX mAbs (Fig. 6a, upper panel).
Gross inspection of tumors at the terminal time point
(day 32) (Fig. 6a, lower panel) and measurement of
tumor mass (Fig. 6b) demonstrated that control mice
had substantially larger tumor burden that broke free of
the subrenal capsule to appose the abdominal wall, while
mice treated with anti-CAIX mAbs had tumors that
remained attached to the kidney parenchyma. These
findings correlate with the BLI analysis (Fig. 5b), and
emphasize that the fully human anti-CAIX mAbs mark-
edly limit tumor growth in vivo.Potential immune mechanisms of anti-CAIX
mAb-mediated tumor inhibition in the allogeneic PBMC
orthotopic model
The NOD/SCID/IL2Rγ−/− (NSG) mouse was selected as
the background strain for these studies because of its
lack of endogenous immune killing mechanisms by
ADCC (natural killer (NK) and myeloid cells) and CDC
activity [35], and its high rate of xenogenic tumor en-
graftment [27]. The lack of tumor growth inhibition
early in treatment (Fig. 5), and significant growth of tu-
mors only in mice not treated with anti-CAIX mAbs
(Fig. 6), raised the question as to what cells might be in-
volved in facilitating anti-CAIX mAb mediated tumor
growth inhibition. We first examined NK cells in
engrafted tumors on day 11 (one day after mAb injec-
tion and seven days after PBMC injection, Fig. 4b), and
found that there were greater numbers of detectable hu-
man NK cells in the tumors of anti-CAIX mAb-treated
mice than in control-treated mice (Fig. 7a). Although
CD56 staining might also point to NK-T cells, the ratio
of NK:NK-T cells in PBMCs is reported as 15:1 [36] and
their contribution if any, remains to be determined. Hu-
man CD56+NK cells were additionally stained with
CD16+ to detect cells that are active for ADCC [37] in
the periphery of mice on day 11 (3.28 %), but they were
undetectable in either the peripheral blood (Fig. 7b) or
tumors (data not shown) on day 17 (0.25 %). These data
indicate that while NK cells may have affected tumor
growth during the first week after human PBMC injection
Fig. 5 Orthotopic RCC tumor growth following treatment with
anti-CAIX mAbs. (a) Tumor growth was determined in each treatment
group by BLI, following injection of antibodies and human PBMC as
described in Fig. 4. Data represent measurement of three mice and are
representative of two independent experiments. * indicates p value of
two-way ANOVA< 0.05, compared to control IgG. (b) Representative
images of BLI measurement depicted in (a)
Fig. 6 Gross pathological examination of orthotopic tumors. (a) Kidneys
and engrafted tumors were excised from mice at the indicated time
point. Upper panel, white circles indicate area of the kidney where
tumors were injected into the sub-renal capsule. Lower panel, normal
kidneys (left) versus kidneys bearing engrafted tumors (right) from the
indicated treatment groups. All images are taken from one mouse, and
are representative of the indicated treatment group. (b) Tumor weight
was determined by excision of the engrafted tumor on day 32 from the
indicated treatment group
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not detected in the blood of NSG mice at day 17 post
tumor implantation, and therefore did not appear to bedirectly involved in the inhibition of tumor growth that
was seen at later time points.
The simple explanation that the anti-tumor activity
was mediated by myeloid cells still present in NSG
mouse blood or by complement was also investigated.
We performed in vitro killing studies to determine
whether G37 and G119 IgG1 can induce cytotoxicity of
CAIX+ SKRC-59 cells in the presence of non-activated
NSG PBMCs (Additional file 3: Figure S3a) or NSG
serum (Additional file 3: Figure S3b), mouse anti-human
CAIX IgG2a serving as a positive control. As can be
seen, human G119 IgG1 was not effective in inducing
ADCC or CDC whereas the mouse anti-CAIX mAb was
Fig. 7 Human NK cell analysis. (a) Kidneys were excised from mice
one day after antibody injection and examined for human NK cell
influx into the engrafted tumor by immmunofluorescent analysis
of human NK cells (CD56+, red) and contrasted against DAPI (blue).
Data are from the IgG1 and G37 treatment groups, and representative of
control and anti-CAIX treatments, respectively. (b) Human NK cell
populations were analyzed by FACS after gating on human CD45+CD3−
cells in the peripheral blood of mice at day 11 and 17 from mice in the
G37 treatment group, (c) The ADCC of freshly isolated human PBMC (left,
hu-PBMC) and PBMC isolated from NSG mice 32 days after human PBMC
injection from the same donor (hu-NSG PBMC, right) were determined
against RCC cells used to establish orthotopic tumors with control or
G37 IgG1. Data represent means of three measurements. ** indicates
p value of student t-test < 0.01, compared to control IgG1
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efficient engagement of mouse FcγRIII than human
IgG1 [38–41].
Despite the loss of NK cells over time in the model
and lack of ADCC by non-activated NSG myeloid cells,
total PBMCs from these treated mice contained both
human and mouse cells and retained ADCC activity at
the terminal time point (day 32) that was similar to
freshly isolated human PBMCs (Fig. 7c). We therefore
examined other cells that might directly or indirectly
mediate tumor inhibition in the presence of anti-CAIX
mAbs. At day 14 post tumor engraftment, mouse mye-
loid cells (Ly6G+) infiltrated the site of tumor engraft-
ment for all treatment groups (Fig. 8a, upper panel),
suggesting that activated myeloid cells were being re-
cruited. Similarly, human T cells (CD3+) were detectable
in the tumors of all treatment groups two weeks after in-
jection, but these T cells did not exhibit a high level of
PD-1 expression, a marker of activation and exhaustion
[42]. At the terminal time point (32 days after tumor en-
graftment), human T cell and mouse myeloid cell tumor
infiltrates persisted or increased (Fig. 8a, lower panel),
and this infiltration was again similar across all treat-
ment groups. However, when we performed histological
quantification of tumor infiltrates (Fig. 8b), the analysis
revealed that mice treated with G37 mAb have higher
levels of T cells expressing PD-1. To examine if the infil-
trating T cells were activated, serial sections of the
tumor tissue were stained with anti-CD8 and anti-IFN-γ
antibodies. The tumor tissues of anti-CAIX mAbs treated
cases consistently showed remarkable infiltration of CD8+
T cells in all groups (Additional file 4: Figures S4 and
Additional file 5: Figure S5). Moreover, the IFN-γ-staining
T cells from anti-CAIX mAbs treated tumor tissues dis-
tinctly showed more dense staining of positive cells com-
pared to control IgG1-treated group. Together, these
findings suggest that, in the presence of anti-CAIX mAbs,
the tumor inhibition seen at later time points in our
model may involve both activated T cells and endogenous
(Ly6G+) mouse myeloid cells.
Discussion
Although treatment of RCC with antibody-based therap-
ies has increased over the last several years [5], cancer
cures with this approach has remained elusive [2, 3].
Various antibodies targeting the tumor-associated anti-
gen CAIX on RCC cells have been amongst those most
extensively studied [8, 21, 23, 24, 34], owing to the anti-
gen’s high expression on RCC. One chimeric anti-CAIX
antibody that does not inhibit enzymatic activity, giren-
tuximab, has been evaluated in the clinic [24, 43]. In pre-
liminary analysis of Phase 3 trial results, an increase in the
duration of disease-free survival was seen only in a sub-
group of younger patients who exhibited high expression
Fig. 8 Histological analysis of immune infiltrates in orthotopic RCC tumors. (a) Immunohistochemical detection of Ly6G+, human CD3+, or
human PD-1+ cells in the tumor sections at day 14 (upper panels) and day 32 (lower panels) of indicated treatment group. Large panels
represent a 10x magnification of the indicated treatment group (rows) for detection of each marker (columns), with the smaller inset of 2x
magnification indicating the magnified area. In each magnification, “K” indicates the mouse kidney and “T” represents the orthotopic tumor. Bars
scale, 150 μm and 750 μm for 10x and 2x magnification, respectively. (b) The cell numbers per mm2 were measured in the tumor sections by
Aperio and ImageScope software from at least three sections of each tumor in the indicated treatment group. * indicates p value of student
t-test < 0.05, compared to control IgG1
Chang et al. Molecular Cancer  (2015) 14:119 Page 8 of 13of CAIX on RCC tumors. Several small molecules known
to effectively inhibit CA have demonstrated particular
promise as potential anti-cancer agents [44, 45]. Thesefindings highlight a need to both more clearly define
patient populations under investigational drug study and
develop novel anti-CAIX antibody drug candidates to
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tumors. Thus, anti-CAIX antibodies that combine inhib-
ition of the enzymatic activity of CAIX with ADCC or
CDC might be more potent than girentuximab.
In this study, we selected several of our anti-CAIX
mAbs for further characterization based on their high af-
finity, capacity to inhibit CA activity, or ability to induce
CAIX internalization (Additional file 6: Table S1) [23].
Our findings indicate that when CAIX-expressing RCC
cells were simultaneously incubated with internalizing or
non-internalizing anti-CAIX mAbs and PBMCs, ADCC
activity of the antibodies showed no correlation with
their reported capacity to induce CAIX internalization
(Fig. 1). Similarly, the capacity to induce CAIX internal-
ization did not affect the ability of anti-CAIX mAbs to
limit RCC motility, as both G37 (non-internalizing) and
G119 (internalizing) IgG1 demonstrated comparable in-
hibition of RCC expansion and movement in vitro (Fig. 2).
In addition, Fc engineering to enhance effector activity
[31] increased the ADCC mediated killing of RCC by both
mAbs (Fig. 3a), but had only marginal effects on CDC and
phagocytosis (Figs. 3b and c). This enhanced in vitro
ADCC killing activity did not translate into more potent
inhibition of tumor growth in vivo. However, this may
have occurred because of the high doses (10 mg/kg) and
frequent treatments (2x/week) of the anti-CAIX mAbs.
Additional dose response studies on the wild type and Fc
mutated mAbs should be performed in future studies to
determine if an enhancement in potency of tumor killing
activity by Fc engineered antibodies could be seen at lower
concentrations in vivo.
Animal models examining the efficacy of cancer thera-
peutics increasingly use a xenograft approach where
cancer cell lines or patient derived tumor tissue are im-
planted into immunodeficient mice [27]. These patient-
derived tumor models (PDTM) have been used in several
studies of RCC [33, 34, 46, 47], and offer a promising
means by which targeted therapeutics such as tyrosine
kinase inhibitors can be evaluated. A caveat to this ap-
proach, however, is that the complexities of tumor and im-
mune cell interactions are not evaluated in current RCC
PDTM, and therefore these critical parameters are often
missing or underrepresented in the analysis [33]. This
shortcoming is mirrored in the analysis of antibody thera-
peutics, most immediately because of a lack of a functional
immune system in mice engrafted with human tumors.
We sought to circumvent this by developing an allogeneic
mouse model whereby the capacity of antibody therapies
against CAIX can be evaluated (Fig. 4). To this end, we
created a model wherein human donor PBMC with a
demonstrated capacity to kill CAIX+ RCC cells by ADCC
(Additional file 2: Figure S2) were injected into mice bear-
ing an orthotopic RCC tumor. To characterize the tumor
killing activity mediated by anti-CAIX mAbs, a luciferase-expressing CAIX+ RCC cell line was transplanted orthoto-
pically to facilitate measurement of tumor growth. We an-
ticipated that these efforts would afford us the capacity to
examine the efficacy of anti-CAIX mAbs in the presence
of human immune cells to inhibit tumor growth in vivo.
While our mouse model demonstrated that both wild
type and mutant Fc formats of anti-CAIX G37 and G119
IgG1 were capable of limiting tumor growth, this obser-
vation did not manifest by BLI until circa three weeks
after PBMC and anti-CAIX treatment (Fig. 6). A possible
reason for the delay in detecting tumor inhibition may
be the limitations of BLI sensitivity in measuring small
orthotopic tumors. Alternatively, tumor inhibition may
have been delayed because several subsets of immune
cells in human PBMCs do not persist in the NSG mouse
for long periods of time.
Consistent with previous reports [48, 49], we were un-
able to detect human NK cells in the mice 13 days after
PBMC injection (Fig. 7b). However, we did find that a
greater influx of human NK cells occurred in tumors
one day after antibody injection (7 days after PBMC in-
jection) in mice treated with anti-CAIX mAbs (Fig. 7a).
This indicates that, while human NK cells do not persist,
these cells likely contributed to early inhibition of tumor
growth by the anti-CAIX mAbs, which did not manifest
overtly until much later time points.
An additional possibility for the inhibition of tumor
growth seen in anti-CAIX mAb-treated mice may in-
volve the influence and interaction of human T cells and
mouse myeloid cells. Human T cells infiltrating the
engrafted tumor appear most activated at later time
points in our model, as measured by expression of hu-
man PD-1 and IFN-γ [42] (Fig. 8 and Additional file 4:
Figure S4). This activation of human T cells is coincident
with mouse myeloid influx in the tumor. While the mye-
loid compartment in NSG mice has been characterized
as deficient [50], it is possible that shed CAIX/anti-
CAIX complexes can active the mouse myeloid compart-
ment and through direct cellular interactions and cyto-
kine secretion lead to further activation of human T cells
to express PD-1 (Fig. 8b) [51]. It is also possible that
graft versus host disease [52] or HLA-mismatch with the
engrafted tumor can act in concert with anti-CAIX
mAbs and mouse myeloid cells to enhance CAIX+
tumor cell killing. It should also be noted that the
SKRC-59 cells used for the in vivo studies herein are
CAIX+PD-L1+ (data not shown) and therefore the po-
tential role that the PD1:PD-L1 checkpoint control axis
may play in limiting the Teff response must also be
considered.
Finally, PBMC from the terminal time point (including
both human immune and mouse myeloid cells) demon-
strate ADCC activity, despite lacking human NK cells,
which suggests that enhancement of NSG myeloid cell
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demonstrates a lack of CDC activity in vivo (Additional
file 3: Figure S3b) owing to a 2-base pair deletion in the
complement C5 structural gene [53], it is possible that
anti-CAIX deposition on the tumor cells can lead to ac-
tivation of earlier complement components including
C3a and C4a that can lead to chemotactic recruitment
of myeloid cells and C3b to promote opsonization. Both
of these actions could lead to myeloid cell activation and
enhanced tumor killing activity [54]. This speculation
clearly requires more extensive characterization of infil-
trating human T cell and mouse myeloid cell activity in
the tumor. Therapeutic antibodies targeting the PD-
1:PD-L1 axis [55, 56] in combination with anti-CAIX
mAbs would be particularly amenable to assessment
with our model as PD-L1 is known to be expressed on
RCC cells and associated with poor outcome [57].Conclusions
Recent clinical trials [26] highlight the pressing need for
the development of novel therapeutics targeting CAIX
on RCC and other cancers [16, 24]. This work demon-
strates that, in addition to previously described charac-
teristics [23], several of our high affinity, fully human
anti-CAIX mAbs mediate potent ADCC and are efficient
in eliciting immune mediated killing of RCC. Our devel-
opment of a novel orthotopic RCC model utilizing allo-
geneic human PBMC confirms the capacity of these mAbs
to mediate tumor growth inhibition in vivo. Our study
provides promising new data that supports further clinical
development of these anti-CAIX mAbs, particularly in
regards to patients that are poised to most immediately
benefit from CAIX-targeting therapeutics [5, 26] in RCC.
In addition, the recently defined role of CAIX in the inci-
dence and progression of breast cancer [58–61] offers an-
other potential means by which the dual-targeting
capacity of these anti-CAIX mAbs may be leveraged.Materials and methods
Cell lines and culture
Human renal clear cell carcinoma (RCC) cell lines,
SKRC-09 (CAIX positive), SKRC-52 (CAIX positive),
and SKRC-59 (CAIX negative), were obtained from Dr.
Gerd Ritter (Memorial Sloan-Kettering Cancer Center,
New York, NY). These lines were grown in RPMI 1640
Medium (Life Technologies) supplemented with 10 %
(v/v) heat-inactivated fetal bovine serum (FBS, Gibco),
100 IU/ml penicillin and 100 μg/ml streptomycin
(complete medium) at 37 °C with 5 % CO2. RCC4 and
293 T cells (CRL-11268, ATCC) were grown in DMEM
Medium (Life Technologies) supplemented with 10 %
FBS, 100 IU/ml penicillin and 100 μg/ml streptomycin.
The 293 F cell line (Life Technologies) was propagatedand transfections for protein production carried out in
293 FreeStyle serum-free medium (Life Technologies).
Antibodies and flow cytometry analysis
Anti-CAIX antibody variants (G10, G36, G37, G39, and
G119) and control antibody were produced as described
previously [23, 30]. Briefly, scFv-Fcs were constructed by
cloning the single-chain variable region (scFv) in frame
with a human IgG1 Fc region lacking a CH1 domain.
Full length, human IgG1s were generated by cloning
heavy chain variable region (VH) and light chain variable
region (VL) into a dual-promoter expression cassette [4].
Antibodies (scFv-Fc and IgG1) were transfected into
293 F cells using polyethylenimine and purified by pro-
tein A sepharose affinity chromatography via ÄKTAPuri-
fier FPLC (GE Healthcare). To characterize nature killer
cells, cells were stained with human CD45, CD56 and
CD16 antibodies (BioLegend) and analyzed by flow
cytometry.
Antibody-dependent cell-mediated cytotoxicity assay
Cytotoxicity assays utilized measurement of lactose de-
hydrogenase (LDH) release, with PBMC from healthy
human donors or NSG mice used as effector cells. RCC
cell lines SKRC-09, SKRC-52, SKRC-59, or CAIX+
SKRC-59 (engineered to express CAIX by lentiviral
transduction [23]) were used as target cells and plated at
1 × 104/well in a 96-well plate. Cells were incubated with
indicated concentrations of antibody for one hour,
followed by co-culture with effector cells for 4–6 h [4].
Culture supernatants were harvested by centrifugation
and LDH measured in the supernatant by colorimetric
assay (Promega) at 490 nm. The percent cytotoxicity
was calculated as: %Cytotoxicity = 100 × (E – SE – ST)/
(M – ST); E, released LDH from E/T culture with anti-
body; SE, spontaneous released LDH from effectors; ST,
spontaneous released LDH from targets; M, the max-
imum released LDH from lysed targets. All tests were
performed in triplicate.
Complement dependent cytotoxicity assay
SKRC-52 cells were cultured in 96 well plates (2 × 104/
well) RPMI 1640 Medium (Life Technologies), supple-
mented with 100 IU/ml penicillin and 100 μg/ml
streptomycin, and rabbit serum (Cedarlane Laborator-
ies). Control or CAIX antibodies were added at the indi-
cated amounts and cytotoxicity measured as in ADCC
assays by LDH release after 6 h. Cytotoxicity was calcu-
lated as: %Cytotoxicity = 100 × (E – ST)/(M – ST). All
tests were performed in triplicate.
Migration assay
Migration of SKRC-52 cells was determined by transwell
assay using FluoroBlok 24-multiwell insert assay (BD
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cells were labeled with a lipophilic fluorescent dye DiO
(Life Technology) and seeded in the upper chamber at
1 × 105 cells/well in 0.5 % FBS RPMI in the presence or
absence of 2.5 μg/ml G37, G119, a non-specific IgG1, or
100 μM of acetazolamide as a positive control for inhib-
ition of migration. Hepatocyte growth factor (HGF,
Sigma) was added into the lower chamber. Fluorescence
intensity of the lower chamber, indicating cell migration,
was measured after 24-h incubation at 37 °C using a
POLARstar reader (BMG Labtech). All tests were per-
formed in triplicate.
Wound healing assay
SKRC-52 cells were cultured to confluency in 24-well
plates (approximately 2 × 105 cells/well). The monolayers
were incubated in the absence of serum for 16 h and
wounded in a line across the well with a 200-μl pipette
tip. The wounded monolayers were washed twice with
serum-free media and incubated with 10 μg/ml of G37,
G119, a non-specific IgG1, or 100 μM acetazolamide.
The area of cell-free wound was recorded 24-h later
using a charge-coupled device camera (C2400; NEC) on
an inverted microscope (Axiovert 35; Zeiss) and ana-
lyzed with image analysis software (NIH Image 1.55).
Wound healing was calculated as the percentage of the
remaining cell-free area compared with the area of the
initial wound. All tests were performed in triplicate.
Cell growth inhibition assay
SKRC-52 cells were seeded in 96-well plates at a density
of 4 × 103 cells/well. After 24 h, cells were incubated
with anti-CAIX antibodies or control antibody in fresh
medium. Followed by 24, 48, 72, 96, and 120 h incuba-
tion, MTT (2 mg/ml in RPMI, 50 μl/well) was added to
the wells and further incubated at 37 °C for 2.5 h. The
supernatant was removed and 150 μl DMSO per well
was added to dissolve the produced formazan. After
shaking the plates for 10 min, optical absorbance at 570
nm were recorded with a microplate reader.
Antibody dependent cellular phagocytosis assay
CD14 positive monocytes were isolated from healthy
donor whole blood by fluorescent activated cell sorting
(FACS), and cultured in 10 cm2 dishes with complete
medium supplemented with 200 U/ml granulocyte macro-
phage colony-stimulating factor (GM-CSF, eBioscience).
Culture medium was refreshed every other day for 5 days,
non-adherent cells were washed away with PBS and the
adherent monocyte-derived macrophages (MDMs) har-
vested. SKRC-52 cells were labeled with PKH-26 fluores-
cent membrane dye (Sigma), washed three times,
incubated on ice for 1 h without antibody or CAIX anti-
bodies, and cultured with MDMs at a 1:8 ratio for 4 h at37 °C. Phagocytosis was determined after extensive
washing of the co-culture, and measured by FACS as
CD14+PKH+ cells. The percentage of phagocytosis was
calculated as: %Phagocytosis = 100 × [(percent dual posi-
tive)/(percent dual positive + percent residual targets)]. All
tests were performed in triplicate.
Orthotopic RCC tumor: allogeneic human PBMC model
Orthotopic RCC tumors were established by injecting
5 × 104 SKRC-59 cells into the left subrenal capsule of
kidneys of NSG mice. SKRC-59 cells were engineered to
express high levels of human CAIX and luciferase,
through lentiviral transduction, and passaged subcutane-
ously in NSG mice prior to engraftment to enrich for
rapidly growing, CAIX+ cells (data not shown). Prior to
injection, RCC cells were suspended in PBS and diluted
1:1 in Matrigel (Life Technologies) to ensure retention
of the cells within the subrenal capsule. Three days after
engraftment, tumor implantation was confirmed by bio-
luminescence imaging (BLI) using a Xenogen imaging
system (Life Technology) with subsequent measure-
ments taken every 3–4 days thereafter. Four days after
tumor engraftment, 1×107 PBMC from a healthy human
donor (selected for high ADCC activity) were injected
intravenously. Six days after PBMC injection (10 days
after engraftment) control or CAIX antibodies were
injected at 10 mg/kg intravenously, and subsequently
injected every 3–4 days thereafter. Mice were sacrificed
and tissues harvested at 32 days post tumor engraftment.
Animal care was carried out in accordance with the
guidelines of Animal Care and Use Committee of Dana-
Farber Cancer Institute.
Histology
RCC tumors and kidneys were surgically removed, fixed
in 10 % neutral buffered formalin, embedded in paraffin,
and 6-μm thick sections placed on slides. Hemotoxylin
and eosin (H&E) immunostaining was performed using
anti-human CD3 (A0452, DAKO), anti-human PD-1
(315 M–96, Cell Marque), anti-mouse Ly6G (1A8, Bio-
Legend), anti-IFN-γ (MD-1, BioLegend), and anti-CD8
(M7103, DAKO) antibodies. HRP-labeled anti-rabbit
antibodies (Pierce) and Mouse on Mouse (M.O.M.) Kits
(Vector) were used as secondary antibodies and detected
by diaminobenzidine according to the manufacturer’s in-
structions. Imaging of sectioned tissues was carried out
using the ScanScope system (Aperio) and the Image-
Scope software at the Dana-Farber/Harvard Cancer Center
Tissue Microarray and Imaging Core. Tumor sections for
immunofluorescent staining was performed as above, but
with 4’,6-diamidino-2-phenylindole (DAPI, Life Technolo-
gies) and phycoerythrin (PE) mouse anti-human CD56
(MEM188, BioLegend). Fluorescent images were acquired
on a Leica confocal microscope (TCS-SP5-AOBS) and
Chang et al. Molecular Cancer  (2015) 14:119 Page 12 of 13images overlaid using Leica application suite advanced
fluorescence software.Statistical analysis
Data was analyzed using two-sided unpaired Student’s
t-test or two-way ANOVA. *, **, and *** indicate p < 0.05,
0.01 and 0.005, respectively. All values and bars are repre-
sented as mean +/− standard deviation (S.D.) or standard
error of the mean (S.E.M.).Additional files
Additional file 1: Figure S1. The antibody-mediated killing activities on
CAIX expressing RCC4 tumor cells. (a) Anti-CAIX antibodies (G37 and G119)
were tested for ADCC activity with human PBMCs in a dose dependent
manner. CAIX+ RCC4 cells were incubated with human PBMCs at an
indicated ratio and 5 μg/ml of antibodies, and cytotoxicity measured by
LDH release in the culture supernatant. Data represent triplicate wells of one
experiment. (b) CDC activity was determined by culture of rabbit serum with
RCC4 cells, and cytotoxicity measured as above after 6 h. All data points
represent the mean value ± S.D. *, **, and *** represent p value of Student
t-test < 0.05, 0.01, and 0.005, respectively.
Additional file 2: Figure S2. Selection of human PBMC with high
ADCC activity. Human PBMC, isolated from twenty-one healthy donors
were cultured with CAIX+ SKRC-59 cells (25:1 PBMC: RCC) in the presence
of the indicated concentration of anti-CAIX G37. ADCC activity was
measured as described in Materials and Methods, with donor 7 (D7) was
chosen as the source of human PBMC utilized in the in vivo mouse model
construction. Data represent the mean of triplicate measurements, ± S.D.
Additional file 3: Figure S3. The antibody-mediated killing activities on
CAIX expressing tumor cells through NSG blood or serum. (a) Human
anti-CAIX mAbs (G37 or G119) and mouse antihuman CAIX antibody,
MAB2188, were tested for ADCC activity against CAIX+ SKRC-59 cells.
NSG mouse PBMCs were isolated from untreated NSG mice, and total
PBMC counted as effector cells (E) in co-culture with the respective target
CAIX+ SKRC-59 cells (T) for six hours. The concentration of antibodies was
5 μg/ml. (b) CDC activity was determined by culture of NSG mouse
serum with CAIX+ SKRC-59 cells, and cytotoxicity measured as above
after 6 h. Culture supernatant was examined for LDH as a measure of
cytotoxicity. Data represent the mean of three independent experimental
values, ± S.D.. * represents p value of Student t-test < 0.05.
Additional file 4: Figure S4. IFN-γ and CD8+ T cells staining on
orthotopic RCC tissues. Representative immunohistochemical staining for
IFN-γ (upper two lanes) and CD8 (lower lane) in the tumor sections at
day 32 was shown by the indicated treatment group. Anti-IFN-γ and
anti-CD8 antibodies were detected by DAB (shown as brown particles)
and indicated by arrows. Bars represent 50 μm.
Additional file 5: Figure S5. IHC staining for HRP-labeled secondary
anti-rabbit antibody and mouse on mouse (M.O.M.) kit. Representative
immunohistochemical staining for HRP-labeled anti-rabbit antibody
(upper) and M.O.M. kit (lower) in the tumor sections at day 32 was shown
by the G37 treatment group. Sections were further detected by DAB. Bars
represent 100 and 50 μm in 40X and 20X, respectively.
Additional file 6: Table S1. The kinetic constants of all anti-CAIX
antibodies were obtained by global analysis using a 1:1 langmuir binding
model and the T100 evaluation software. Percentage of carbonic anhydrase
inhibition by CAIX antibodies was estimated from an electrometric assay.
Internalization measured by both flow cytometry and ImageStream. +
denotes degree of internalization as measured by regular flow cytometry.Competing interests
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